Identifying High-Risk Stage I NSCLC Patients With a Tumor-Informed Plasma ctDNA Assay

Circulating tumor DNA (ctDNA) has emerged as an important prognostic factor in patients with cancer. Management of early stage NSCLC remains challenging with a high rate of disease recurrence.